Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai 200011, PR China.
Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai 200011, PR China; Vascular Center of Shanghai JiaoTong University, Shanghai, 200011, PR China.
Int J Cardiol. 2021 Apr 1;328:69-74. doi: 10.1016/j.ijcard.2020.12.011. Epub 2020 Dec 17.
Retrograde type A dissection (RTAD) is a rare but life-threatening event following thoracic endovascular aortic repair (TEVAR), and its total endovascular treatment is a huge challenge. This research aimed to evaluate the safety, effectiveness, technical success, and medical outcomes of in situ laser fenestration of aortic arch stent grafts during TEVAR of RTAD.
We retrospectively reviewed the clinical data of 15 patients with RTAD who received in situ laser fenestration of aortic arch stent grafts during TEVAR between Mar 2016 and Dec 2019. All patients were subjected to intraoperative extracorporeal brain perfusion. The preoperative, intraoperative and postoperative medical data were collected and analyzed.
The mean age of the 15 patients was 64 ± 8 years, 8 of whom were male. The immediate overall technical success rates, including aortic stent deployment were 100% and primary fenestration success was achieved in 13 (86.7%) patients. The mean postoperative length of stay was 10 ± 4 days. Stroke occurred in 1 case. No in-hospital/30-day death nor permanent paraplegia/paresis was observed. The mean follow-up time was 13 ± 5 months. Two type Ia endoleaks were found, but no late occlusion and migration of the supra-aortic branch arteries stents during the follow-up were observed.
The in situ laser fenestration of aortic arch stent grafts during TEVAR of RTAD is a potential total endovascular therapy of RTAD for patients unsuitable for direct surgical repair.
逆行性 A 型夹层(RTAD)是胸主动脉腔内修复术(TEVAR)后一种罕见但危及生命的事件,其完全腔内治疗是一个巨大的挑战。本研究旨在评估原位激光开窗主动脉弓支架移植物在 TEVAR 治疗 RTAD 中的安全性、有效性、技术成功率和医疗效果。
我们回顾性分析了 2016 年 3 月至 2019 年 12 月期间 15 例接受原位激光开窗主动脉弓支架移植物 TEVAR 的 RTAD 患者的临床资料。所有患者均接受术中体外脑灌注。收集并分析了术前、术中及术后的医疗数据。
15 例患者的平均年龄为 64±8 岁,其中 8 例为男性。主动脉支架置入的即刻总体技术成功率为 100%,13 例(86.7%)患者实现了原发性开窗成功。术后平均住院时间为 10±4 天。1 例发生卒中。无院内/30 天死亡或永久性截瘫/轻瘫。平均随访时间为 13±5 个月。发现 2 例Ⅰa 型内漏,但在随访期间未发现主动脉弓分支动脉支架晚期闭塞和移位。
TEVAR 治疗 RTAD 时原位激光开窗主动脉弓支架移植物是一种潜在的 RTAD 完全腔内治疗方法,适用于不适合直接手术修复的患者。